Julie M. Vose, MD; Philip J. Bierman, MD; James O. Armitage, MD
Although tremendous progress has been made in the treatment of malignant lymphomas, patients who fail to achieve a complete remission with standard chemotherapy or who relapse after an initial complete remission have a 2-year disease-free survival of less than 5% with routine "salvage" chemotherapy (1-3). In an attempt to overcome the intrinsic resistance of the malignant cells, high-dose chemotherapy and autologous bone marrow transplantation have been used in this patient population. Data from several studies conducted in patients with relapsed lymphoma undergoing high-dose chemotherapy and autologous bone marrow transplantation indicate a 2-year disease-free survival ranging from 20% to 45% (4-6).
Learn more about subscription options.
Register Now for a free account.
Vose JM, Bierman PJ, Armitage JO. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Answers or More Questions?. Ann Intern Med. 1992;116:261–262. doi: 10.7326/0003-4819-116-3-261
Download citation file:
Published: Ann Intern Med. 1992;116(3):261-262.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only